PHOENIX, April 12,
2022 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. ("Creative Medical Technology" or the "Company")
(NASDAQ: CELZ), a leading commercial stage biotechnology company
focused on a regenerative approach to immunotherapy, urology,
neurology and orthopedics, today announced that it will be
exhibiting at the American Urological Association ("AUA") Annual
Meeting on May 13-16, 2022 in
New Orleans to showcase
CaverStem®, the only patented procedure performed by a licensed
physician that provides a safe, effective solution to treat
erectile dysfunction using the patient's own stem cells to repair
damaged tissue.
"With the addition of team members with decades of experience in
medicine and medical marketing, we are excited to present
CaverStem® to this very prominent group of practicing physicians.
CaverStem® is backed by clinical trial results published in a peer
reviewed journal and supported by testimonials from patients that
have had life-changing positive results," said Timothy Warbington, President and CEO of
Creative Medical Technology.
Notable accomplishments:
- Landmark clinical trial results published in Journal of
Translational Medicine showing strong efficacy and no major
adverse effects (Link)
- Protocol optimized to eliminate the need for centrifuge –
reducing capital equipment cost and streamlining the procedure for
providers and patients
- Exclusive rights for the use of the FDA approved device
- Expanding physician network – validation not only of the
technology, but the lucrative business model
- Consumer awareness programs optimized to support healthcare
providers with outreach
The Company's presenters at the conference will include Dr.
Naveen Kella from The Urology Place
(www.TheUrologyPlace.com), who has successfully performed over 50
procedures at his San Antonio,
TX location. Dr. Kella will share his experience from
training to the ongoing support he receives from Creative Medical
Technology and the impact it has had on his practice and
patients.
"We initially read the study on CaverStem® and after talking to
other providers were encouraged about this technology. I am excited
to present my own experience with this treatment for which we are
collecting data on outcomes," said Dr. Kella.
The Company plans to utilize the AUA event to share updated data
on CaverStem and recruit additional providers.
Interested in becoming a provider:
You do not have to wait until the conference begins to get
started as a provider. To get started, simply complete the
form here: https://caverstem.com/become-a-provider/.
About Dr. Naveen Kella:
Dr. Naveen Kella is board certified in urology, with a
fellowship in Urologic Oncology and Robotic Surgery. He is known
for his experience in treating prostate cancer and has performed
over 3,000 robotic prostate cancer surgeries. He has a strong
interest in finding ways to continually minimize treatment
side-effects.
About Erectile Dysfunction:
Erectile dysfunction (ED) is characterized by the lack of
ability to achieve and maintain penile erection for
intercourse. Methods used to quantify ED include the Erectile
Function Visual Analog Scale (EF-VAS) and the International Index
of Erectile Function (IIEF-5), however clinically it is primarily
diagnosed based on symptomology. In our aging society, ED is
becoming an increasing problem. According to one study, 39% of men
at age 40 experience symptoms of ED, whereas by age 70 the
incidence rises to 67%. In this latter age group, it is believed
that 50-85% of ED cases are associated with hypertension, diabetes,
cardiovascular disease and dyslipidemia. Overall, it is
estimated that 10-30 million Americans suffer from this
condition.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company specializing in regenerative medicine in the
fields of immunotherapy, urology, neurology and orthopedics. For
further information about the company, please visit
www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and
content of upcoming clinical trials and laboratory results,
marketing efforts, funding, etc. Forward-looking statements address
future events and conditions and, therefore, involve inherent risks
and uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-to-showcase-caverstem-at-american-urological-association-annual-meeting--largest-and-most-prominent-gathering-of-urologists-in-the-world-301523499.html
SOURCE Creative Medical Technology Holdings, Inc.